选择语言

关注公众号

ADC偶联试剂盒——快、准、稳的偶联体验

ADC（抗体药物偶联物）是 “抗体 - 连接子 - 细胞毒性载荷” 构成的靶向药物，核心是通过偶联技术将细胞毒性载荷（如 MMAE、DXd）精准连接到抗体上，实现 “靶向递送毒性药物至肿瘤细胞” 的效果 ——偶联技术决定载荷如何高效、稳定地与抗体结合，直接影响 ADC 的药效、安全性和生产可行性。

为满足高效、精准的ADC偶联需求，ACROBiosystemstyc122ccvip全新推出的ADC偶联试剂盒，为您带来“快、准、稳、简” 的ADC制备体验，3 小时内即可生成ADC产物，保证抗体活性与高回收率，得到的ADC产物可用于细胞或动物实验，以筛选合适的候选ADC药物。

偶联原理：

本试剂盒基于链间半胱氨酸偶联技术开发：抗体的链间二硫键可以被还原产生内源性链间半胱氨酸残基，具有马来酰亚胺官能团的有效载荷药物可以特异性偶联这些半胱氨酸残基并形成结构稳定的ADC。依靠这种经典的偶联策略，本试剂盒能够实现快速可控的ADC制备，只需要3个小时即可获得DAR值均一的ADC偶联产物，且获得的ADC偶联物表现出显著的细胞毒性作用，为ADC药物筛选和机制研究提供了可靠的实验工具。

tyc122ccvip特征:

偶联时间短：3 小时内即可生成抗体药物偶联物（ADCs）

药物抗体比率（DAR）值可控：可精准调控 DAR，同时保留良好抗体活性

偶联效率与回收率高：偶联效率 > 95%，抗体回收率 > 80%

无需高浓度抗体：仅需 2 mg/mL 的抗体浓度即可实现反应

纯化简单：使用离心脱盐柱，15 分钟内即可完成纯化

实验流程：

1. 配制抗体溶液：使用1×PBS缓冲液（pH 7.2-7.4）将抗体浓度配制为2 mg/mL

2. 抗体还原：37℃，1小时

3. 抗体偶联：23℃，1小时

4. 终止反应：室温条件下静置0.5小时

5. 纯化与缓冲液置换：进行产物纯化并更换缓冲体系

ADC 偶联试剂盒tyc122ccvip列表

试剂盒组分

以ADC Conjugation Kit (MMAE, DAR4, 200ug, for human IgG1)（货号：ADC-P013为例）：

tyc122ccvip货号	组分ID	组分名称	规格(1盒)	储存条件
Box A ADC-P013	C01	Reducing reagent	1 vial	-20℃
	C02	VcMMAE	1 vial	-20℃
	C03	Quencher reagent	1 vial	-20℃
Box B ADC-P013-1	Buffer01	1xPBS (pH7.2-7.4), 11%Trehalose	5 mL	4℃
Box B ADC-P013-1	Desalting column	Desalting Spin column, 0.5mL	1 per	4℃

验证数据

以下ADCtyc122ccvip使用ADC偶联试剂盒（MMAE, DAR4, 200ug, for human IgG1, 货号：ADC-P013）制备。

抗体信息：曲妥珠单抗生物类似物。

DAR值及纯度HPLC验证 (HIC+SEC)

Figure 1. The ADC was prepared using the ADC Conjugation Kit (MMAE, DAR4) and analyzed by HIC and SEC-HPLC. The average drug-antibody ratio (DAR) is 4.0±0.5, and the purity of the ADC is greater than 95%.

DAR值质谱验证

Figure 2. The DAR (3.82) was calculated from the weighted average of the deconvoluted MS peak areas using LC-MS/MS. The results showed the deconvoluted mass spectra of light chains and heavy chains, and the increase in molecular weight caused by the coupling payload (1316±3 Da). The heterogeneity in N-glycosylation of heavy chain adds to the complexity of the mass spectrum.

抗原结合能力验证

Figure 3. Binding affinity of anti-Her2 antibody and anti-Her2 antibody–MMAE conjugate to human Her2 (Cat. No. HE2-H5225) as determined by BLI (Bio-Layer Interferometry). The conjugate exhibits nanomolar affinity (0.57 nM) for human Her2, comparable to the naked antibody (0.86 nM).

体外细胞毒性验证

Figure 4. In vitro cytotoxicity assays: The ADC can bind and internalize in target cells (SK-BR-3) with high expression of Her2 and release MMAE inside the cells to induce a cytotoxic effect (IC₅₀=0.0058 µg/mL). Meanwhile, no cytotoxicity was observed in Her2 receptor-negative cell lines (MDA-MB-231).

不同规格Kit一致性验证

Figure 5. In vitro cytotoxicity of products prepared by different size of the ADC Conjugation Kit (Cat. No. ADC-P013, ADC-P014). The result shows very high consistency (RSD＜10%).

稳定性验证

Figure 6. The MMAE-ADC was prepared using the ADC Conjugation Kit, which were left at 37℃ for 21 days. The ADCs were analyzed by HIC and SEC-HPLC. The average drug-antibody ratio (DAR) is 4.0±0.5, and the purity of the ADC is greater than 95%.